ClinicalTrials.gg
CompletedNCT05227196Updated Sep 19, 2024

A Research Study Looking at the Comparability of 2 Different Forms of Oral Semaglutide in Healthy People

A Phase 1 interventional study of Semaglutide D Dose 1 and Semaglutide D Dose 2 in Healthy Volunteers and Type 2 Diabetes, sponsored by Novo Nordisk A/S. Completed at 3 sites in 2 countries. Open to participants aged 18 Years to 64 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-09-19.

Sponsored by Novo Nordisk A/S · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Jun 2023, 3 years 4 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
546
Allocation
Randomized
Ages
18 Years to 64 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 643 studies in Diabetes Mellitus, Type 2 by Novo Nordisk A/S — 25 open to participants now, 29 under way, 11 of them phase 3. Diabetes Mellitus, Type 2 · Novo Nordisk A/S.

Enrollment
85th of 428
546 · median 209
Started
2022
with 23 others
Phase 1
129 of 643
5 open now
Registered
550th of 643
by date

Among the 643 studies in Diabetes Mellitus, Type 2 by Novo Nordisk A/S, this one is the 85th largest by enrollment of the 428 interventional ones that give a count, is one of 24 that started in 2022, is one of 129 in phase 1, and was the 550th registered.

Diabetes Mellitus, Type 2

10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

25 of the 643 studies in Diabetes Mellitus, Type 2 by Novo Nordisk A/S are open now, in 12 countries. Recruiting first, the newest first:

20 more — sign in →

By country, each count listing its studies:

All 25 open studies →

Who these studies take

Of the 880 Diabetes Mellitus, Type 2 studies recruiting now, 374 (43%) set no upper age limit and 380 (43%) stop at 75 or younger; 52 take children under 18; 204 take healthy volunteers.

This study: 18 Years to 64 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 643 studies in Diabetes Mellitus, Type 2 by Novo Nordisk A/S, or all of them as a file.
02

Study summary

The aim of this study is to investigate the amount of the active ingredient and helping agent in the blood in two different tablet versions of Semaglutide. The study will consist of 3 groups and the treatment the participants will get is dependent on the group the participants will be enrolled in.

The participants in group 1 will receive treatment for 22 weeks, group 2 for 21 weeks and group 3 for 20 weeks.

The study will last up to 29 to 31 weeks for each participant. This includes a screening period (up to 4 weeks), a dose escalation period (up to 2 weeks), a treatment period (20 weeks) and a follow-up period (5 weeks after the last dose).

03

Conditions studied

  • Healthy Volunteers
  • Type 2 Diabetes
04

Who can participate

Ages eligible
18 Years to 64 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female, aged 18-64 years (both inclusive) at the time of signing . - (BMI) between 21.0 and 32.0 kg/m\^2 (both inclusive).
  • Considered to be generally healthy based on the medical history, physical examination, and the results of vital signs, and clinical laboratory tests performed during the screening visit, as judged by the investigator.

Exclusion criteria

Exclusion Criteria:

  • equal to or greater than 6.5 % (48 mmol/mol) at screening.
  • Use of tobacco and nicotine products, defined as any of the below:
  • Smoking more than 5 cigarettes or the equivalent per day
  • Not willing to refrain from smoking and use of nicotine substitute products within 48 hours prior to and during the inpatient periods
  • Presence of gastrointestinal disorders potentially affecting absorption of drugs and/or nutrients, as judged by the investigator.
  • History(a) of major surgical procedures involving the stomach potentially affecting absorption of trial products (e.g. subtotal and total gastrectomy, sleeve gastrectomy, gastric bypass surgery) or current presence of gastrointestinal implant(a).
  • Personal or first-degree relative(s) history of multiple endocrine neoplasia type 2 or medullary thyroid carcinoma(a).

    1. As declared by the participant or reported in the medical records
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
546 participants (actual)

Study arms

  • Experimental
    Group 1 Sequence 1

    Crossover arm

    Drug: Semaglutide D Dose 1 · Drug: Semaglutide D Dose 2 · Drug: Semaglutide D Dose 3 · Drug: Semaglutide Dose 6

  • Experimental
    Group 1 Sequence 2

    Crossover arm

    Drug: Semaglutide D Dose 3 · Drug: Semaglutide Dose 4 · Drug: Semaglutide Dose 5 · Drug: Semaglutide Dose 6

  • Experimental
    Group 2 Sequence 1

    Crossover arm

    Drug: Semaglutide D Dose 1 · Drug: Semaglutide D Dose 2 · Drug: Semaglutide Dose 4 · Drug: Semaglutide Dose 5

  • Experimental
    Group 2 Sequence 2

    Crossover arm

    Drug: Semaglutide D Dose 1 · Drug: Semaglutide D Dose 2 · Drug: Semaglutide Dose 4 · Drug: Semaglutide Dose 5

  • Experimental
    Group 3 Sequence 1

    Crossover arm

    Drug: Semaglutide D Dose 1 · Drug: Semaglutide Dose 4

  • Experimental
    Group 3 Sequence 2

    Crossover arm

    Drug: Semaglutide D Dose 1 · Drug: Semaglutide Dose 4

Interventions

  • DrugSemaglutide D Dose 1

    Tablet given orally

  • DrugSemaglutide D Dose 2

    Tablet given orally

  • DrugSemaglutide D Dose 3

    Tablet given orally

  • DrugSemaglutide Dose 4

    Tablet given orally

  • DrugSemaglutide Dose 5

    Tablet given orally

  • DrugSemaglutide Dose 6

    Tablet given orally

This study also gives Semaglutide. No intervention listed here names it: that was found by reading the record.

06

What researchers measure

Primary outcomes

  1. AUC0-24h,semaglutide,SS Area under the semaglutide plasma concentration-time curve during a dosing interval at steady state (SS)

    h∙nmol/L

    Time frame: 24 hours after the dosing of oral semaglutide on days 35/42/49, 70/77/84, 105/112/119 and 140/147/154.

  2. Cmax,0-24h.semaglutide,SS Maximum semaglutide plasma concentration at steady state

    nmol/L

    Time frame: 24 hours after the dosing of oral semaglutide on days 35/42/49, 70/77/84, 105/112/119 and 140/147/154.

Secondary outcomes

  1. tmax,0-24h,semaglutide,SS Time to maximum semaglutide plasma contraction at steady state

    h

    Time frame: 24 hours after the dosing of oral semaglutide on days 35/42/49, 70/77/84, 105/112/119 and 140/147/154.

  2. Ctau,24h,semaglutide,SS Semaglutide plasma concentration 24 hours after last dose at steady state

    nmol/L

    Time frame: 24 hours after the dosing of oral semaglutide on days 35/42/49, 70/77/84, 105/112/119 and 140/147/154.

07

Study locations

3 sites
  • Altasciences Clinical LA, Inc.
    Cypress, California 90630, United States
  • Altasciences Clinical Kansas, Inc.
    Overland Park, Kansas 66212, United States
  • Altasciences Company Inc.
    Montreal, Quebec H3P 3P1, Canada
08

References and documents

Individual participant data

Plan to share: Yes — According to the Novo Nordisk disclosure commitment on novonordisk-trials.com

Data sharing details ↗ · novonordisk-trials.com

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Feb 2022 to primary completion in Jun 2023, 16 months.

Of 453 industry-sponsored phase 1 interventional studies under Diabetes Mellitus, Type 2, half reached primary completion within 5 months of starting (the median), counting those still running; a quarter within 2 and three quarters within 11. This study's 16 months is above that.

Counting every sponsor, half of 515 studies reached it within 6 months; a quarter within 2 and three quarters within 14.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 2, 2022
First posted
Feb 7, 2022
StartActual
Feb 4, 2022
Primary completionActual
Jun 28, 2023
CompletionActual
Aug 8, 2023
Last update
Sep 19, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 19, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05227196
Lead sponsor
Novo Nordisk A/S
Responsible party
Sponsor
First posted
Feb 7, 2022
Start date
Feb 4, 2022
Primary completion
Jun 28, 2023
Completion
Aug 8, 2023
Last update
Sep 19, 2024

Study contacts

Clinical Transparency (Dept. 2834)
study director · Novo Nordisk A/S

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Semaglutide

Start the discussion